MATCHPOINT

 

Figure 1: Matchpoint cumulative actual and target accrual 

Site Name	Principal Investigator	Number of Patients Recruited
Beatson West of Scotland Cancer Centre	Professor Mhairi Copland	3
Hammersmith Hospital	Dr Dragana Milojkovic	6
King's College Hospital	Dr Jennifer Byrne	3
Nottingham City Hospital	Dr Hugues de Lavallade	1
Royal Liverpool University Hospital	Dr Amit Patel	1
St Bartholomew's Hospital	Dr Matthew Smith	1
The Queen Elizabeth Hospital	Dr Manoj Raghavan	1
St James's University Hospital, Leeds	Dr Kate Rothwell	1
Southampton General Hospital	Dr Deborah Richardson	0

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. 

• Investigator Registration Form [.pdf]
• Site Staff Registration Form [.pdf]
• Delegation Log [.doc]

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the MATCHPOINT Trial Office.

• Protocol version 7.0 28-Nov-18 [.pdf]
• Patient Information Sheet version 7.0 28-Nov-18 [.pdf]
• Informed Consent Form version 6.0 10-Jan-18 [.pdf]
• GP Letter version 1.0 06-Aug-13  [.doc]

• GDPR Notification vA 18-Jul-18 [.pdf]
• Patient GDPR Notification log v1.0 08-Oct-18 [.pdf]

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.

• Version Control Checklist - Investigator Site File version 9.0 28-Feb-19 [.pdf]
• Version Control Checklist - Investigator Site File version 8.0 11-Oct-18 [.pdf]
• Version Control Checklist - Investigator Site File version 7.0 04-Jul-18 [.pdf]
• Version Control Checklist - Investigator Site File version 6.0 05-Mar-18 [.pdf]
• Version Control Checklist - Investigator Site File version 5.0 30-Nov-16 [.pdf]
• Version Control Checklist - Investigator Site File version 4.0 06-Oct-16 [.pdf]
• Version Control Checklist - Investigator Site File version 3.0 21-Jan-16 [.pdf]
• Version Control Checklist - Investigator Site File version 2.0 20-Oct-15 [.pdf]
• Version Control Checklist - Investigator Site File version 1.0 28-Oct-14 [.pdf]

• Version Control Checklist - Pharmacy File version 8.0 28-Feb-19 [.pdf]
• Version Control Checklist - Pharmacy File version 7.0 11-Oct-18 [.pdf]
• Version Control Checklist - Pharmacy File version 6.0 04-Jul-18 [.pdf]
• Version Control Checklist - Pharmacy File version 5.0 05-Mar-18 [.pdf]
• Version Control Checklist - Pharmacy File version 4.0 30-Nov-16 [.pdf]
• Version Control Checklist - Pharmacy File version 3.0 06-Oct-16 [.pdf]
• Version Control Checklist - Pharmacy File version 2.0 20-Oct-15 [.pdf]
• Version Control Checklist - Pharmacy File version 1.0 28-Oct-14 [.pdf]

Amendments

Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.

• Amendment 8 28-Nov-2018 [opens new page]
• Amendment 7 08-May-2018 [opens new page]
• Amendment 6 07-Nov-2017 [opens new page]
• Amendment 4/5 23-Sep-2016 [opens new page]
• Amendment 3 09-May-2016 [opens new page]
• Amendment 2 26-Mar-2015 [opens new page]
• Amendment 1 27-Mar-2014 [opens new page]

Case Report Forms

• Eligibility Form v4.0 [.pdf]
• Registration Form v2.0 [.pdf]
• Baseline Form v4.0 [.pdf]
• Treatment Cycle Form v4.0 [.pdf]
• Transplant Form v3.0 [.pdf]
• Day 100 Transplant Form v2.0  [.pdf]
• Maintenance Month 1 Form v3.0 [.pdf]
• Maintenance Month 2-6 Form v3.0 [.pdf]
• Maintenance Month 6 Onwards Form v3.0 [.pdf]
• Pre-Transplant Month 1 Maintenance Form v1.0 [.pdf]
• Pre-Transplant Monthly Maintenance Form v1.0 [.pdf] 
• Follow Up Form v4.0 [.pdf]
• Deviation Form v2.0 [.pdf]
• Treatment Discontinuation Form v2.0 [.pdf]
• Withdrawal Form v2.0 [.pdf]
• Death Form v2.0 [.pdf]
• Adverse Event Form v3.0 [.pdf]
• Serious Adverse Event Form v3.0 [.pdf]

Guidelines

• CRF Completion Guidelines  [.pdf]
• SAE Form Completion Guidelines  [.pdf]

Other Trial Documents

• Pharmacy Manual v5.0 [.pdf]
• SAE Fax Cover Sheet  [.pdf]
• Summary of product characteristics [.pdf]
• Ponatinib drug order form [.pdf]

Brock, K., Billingham, L., Copland, M., Siddique, S., Sirovica, M., and Yap, C. (2017) Implementing the EffTox Dose-Finding Design in the Matchpoint Trial. BMC Medical Research Methodology. 17 (112), 1-15.

First patient newsletter 20-Mar-15 [.docx]

Chief Investigator
Professor Mhairi Copland

Professor of Translational Haematology and Honorary Consultant
Paul O'Gorman Leukaemia Research Centre
College of Medical, Veterinary and Life Sciences
University of Glasgow
Gartnavel General Hospital
1053 Great Western Road
Glasgow
G12 0ZD

Tel: +44 (0)141 301 7872
Fax: +44 (0)141 301 7898
Email: Mhairi.Copland@glasgow.ac.uk

MATCHPOINT Trial Office
Trial Coordinator:  Mirjana Sirovica                                                          
Trial Monitor: Ylenia Vigo                                 
Trial Management Team Leader:  Sonia Fox 
Trial Statistician: Daniel Slade                          

Centre for Clinical Haematology
Cancer Research UK Clinical Trials Unit (CRCTU)
Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH

Enquiries
Telephone: +44 (0)121 371 7866
Fax:             +44 (0)121 371 7874
Email:         Matchpoint@trials.bham.ac.uk

Trial Entry
Telephone: +44 (0)121 371 7866

Serious Adverse Event Reporting
Fax: +44  (0)121 371 7874              Or            +44  (0)121 371 4398 

Sponsor
University of Birmingham

Correspondence to:
Cancer Research UK Clinical Trials Unit (CRCTU)
Centre for Clinical Haematology
Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH